Eli Lilly and Company
LLY
$745.95
-$4.82-0.64%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 19.56% | 9.69% | 1.53% | -5.56% | 0.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.56% | 9.69% | 1.53% | -5.56% | 0.79% |
| Cost of Revenue | 6.82% | -5.33% | -7.31% | -13.85% | -5.09% |
| Gross Profit | 23.41% | 14.62% | 4.38% | -2.88% | 2.71% |
| SG&A Expenses | 14.40% | 10.69% | 8.23% | 2.17% | -1.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.34% | 9.40% | 5.59% | -0.82% | -0.85% |
| Operating Income | 24.66% | 10.35% | -7.55% | -15.99% | 4.75% |
| Income Before Tax | -3.70% | -6.22% | 16.87% | -6.69% | 10.57% |
| Income Tax Expenses | 134.01% | 123.30% | 45.51% | -1.28% | -2.13% |
| Earnings from Continuing Operations | -16.08% | -17.32% | 14.16% | -7.22% | 11.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.08% | -17.32% | 14.16% | -7.22% | 11.88% |
| EBIT | 24.66% | 10.35% | -7.55% | -15.99% | 4.75% |
| EBITDA | 21.02% | 8.03% | -7.78% | -15.28% | 3.75% |
| EPS Basic | -15.99% | -17.12% | 14.64% | -6.74% | 12.56% |
| Normalized Basic EPS | 24.95% | 10.20% | -8.47% | -17.11% | 5.30% |
| EPS Diluted | -16.02% | -17.10% | 14.78% | -6.73% | 12.49% |
| Normalized Diluted EPS | 25.10% | 10.31% | -8.45% | -17.07% | 5.35% |
| Average Basic Shares Outstanding | -0.14% | -0.25% | -0.39% | -0.57% | -0.63% |
| Average Diluted Shares Outstanding | -0.22% | -0.33% | -0.42% | -0.62% | -0.70% |
| Dividend Per Share | 15.31% | 15.30% | 15.30% | 15.30% | 15.29% |
| Payout Ratio | 0.37% | 0.39% | 0.01% | 0.24% | 0.02% |
